In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

In patients with high-risk HER2-positive breast cancer ... by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. “KATHERINE is a landmark clinical trial that found ...

In patients with high-risk HER2-positive breast cancer ... by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. KATHERINE is a landmark clinical trial that found ...

In patients with high-risk HER2-positive breast cancer ... by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. "KATHERINE is a landmark clinical trial that found ...

“As compared with trastuzumab, T-DM1 improved overall survival with sustained improvement in invasive disease-free survival among patients with HER2-positive early breast cancer with residual ...

In patients with high-risk HER2-positive breast cancer ... by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. The findings, published in the New England Journal ...

Charlotte Bevan appreciated the community’s kindness after her mother, Ellen, was diagnosed with breast cancer.

The statistics are alarming. According to the American Heart Association, one in three women dies from heart disease, yet ...

Now 46 and a breast cancer survivor herself ... and associate director of clinical research at the UPMC Hillman Cancer Center, most of his patients and their families are already aware of the ...

Friday was National Wear Red Day, an event designed to spread awareness about heart health, especially in women. To help get ...